Well treatment methods
US-2020270514-A1 · Aug 27, 2020 · US
US12435263B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12435263-B2 |
| Application number | US-202418664761-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 15, 2024 |
| Priority date | Nov 21, 2023 |
| Publication date | Oct 7, 2025 |
| Grant date | Oct 7, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Treatment fluids for acid stimulation operations and methods related thereto. Treatment fluids comprise: an aqueous acid solution comprising a mineral acid and an organic acid; and a retardation additive comprising: 1-15 wt % of an oleaginous liquid; 5-30 wt % of a fatty alkyl alcohol ethoxylate; 2-40 wt % of at least one of a fatty alkyl ethoxylated ammonium salt, a zwitterionic surfactant, an alkyl ether sulfate salt, or an alkyl ether sulfonate salt; 4-30 wt % of a co-solvent; and 10-85 wt % of an aqueous fluid, each wt % based on a total mass of the retardation additive. Treatment fluids or retardation additives may be oil-in-water emulsions. Treatment fluids may have 0.5-5 gallons per thousand, based on an overall volume of the treatment fluid of the retardation additive. Methods comprise providing and introducing the treatment fluid into a subterranean formation during a stimulation operation.
Opening claim text (preview).
What is claimed is: 1. A treatment fluid comprising: an aqueous acid solution comprising a mineral acid and an organic acid; and a retardation additive, wherein the retardation additive comprises: 1 wt % to 15 wt % of an oleaginous liquid; 5 wt % to 30 wt % of a fatty alkyl alcohol ethoxylate; 2 wt % to 40 wt % of at least one of an alkyl ether sulfate salt; 4 wt % to 30 wt % of a co-solvent; and 10 wt % to 85 wt % of an aqueous fluid, each wt % based on a total mass of the retardation additive, and wherein the retardation additive has a volume concentration in the treatment fluid of 0.5 gallons per thousand (gpt) to 5 gpt, based on an overall volume of the treatment fluid, and, wherein the treatment fluid forms an oil-in-water emulsion. 2. The treatment fluid of claim 1 , wherein the mineral acid comprises 10 wt % to 30 wt % hydrochloric acid solution, by total weight of the hydrochloric acid solution, wherein the organic acid comprises methane sulfonic acid, glutamic acid diacetate, or any combination thereof, and wherein the organic acid comprises an organic acid solution with an acid concentration of 10 wt % to 80 wt %, by total weight of the organic acid solution. 3. The treatment fluid of claim 1 , wherein the mineral acid comprises a mineral acid solution and the organic acid comprises an organic acid solution, and wherein the mineral acid solution and the organic acid solution are in a ratio of 9:1 to 1:1, by volume of the solutions. 4. The treatment fluid of claim 1 , wherein the oleaginous liquid comprises a terpene, a hydrocarbon, a fatty acid ester, or any combination thereof. 5. The treatment fluid of claim 1 , wherein the fatty alkyl alcohol ethoxylate comprises a linear or branched C 6 -C 18 alcohol ethoxylate comprising 3 to 30 ethoxylate repeat units. 6. The treatment fluid of claim 1 , wherein the fatty alkyl ethoxylated ammonium salt is present and comprises at least one functionalized alkyl group having 3 to 30 ethoxylate repeat units. 7. The treatment fluid of claim 1 , wherein the zwitterionic surfactant is present and comprises a C 12 -C 18 betaine, a C 12 -C 18 sultaine, or any combination thereof. 8. The treatment fluid of claim 1 , wherein the alkyl ether sulfate salt or the alkyl ether sulfonate salt is present and comprises an ammonium salt. 9. The treatment fluid of claim 1 , wherein the co-solvent comprises an alcohol, a glycol, a glycol ether, a glycol ester, or any combination thereof.
Related publications grouped by family.
Answers are generated from the same data shown on this page.